Risk factors associated with progression of diabetic retinopathy in eyes treated with panretinal photocoagulation

被引:4
作者
Baek, Sung Uk [1 ]
Park, Min Seon [1 ]
Cho, Bum-Joo [1 ]
Park, In Won [1 ]
Kwon, Soonil [1 ]
机构
[1] Hallym Univ, Coll Med, Sacred Heart Hosp, Dept Ophthalmol, 22 Gwanpyeong Ro,170beon Gil, Anyang 14068, South Korea
基金
新加坡国家研究基金会;
关键词
MEAN PLATELET VOLUME; RANIBIZUMAB; METAANALYSIS; SEVERITY; THERAPY; MARKER;
D O I
10.1038/s41598-021-93384-5
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Uncontrolled diabetes has been associated with progression of diabetic retinopathy (DR) in several studies. Therefore, we aimed to investigate systemic and ophthalmic factors related to worsening of DR even after completion of panretinal photocoagulation (PRP). We retrospectively reviewed DR patients who had completed PRP in at least one eye with a 3-year follow-up. A total of 243 eyes of 243 subjects (mean age 52.6 +/- 11.6 years) were enrolled. Among them, 52 patients (21.4%) showed progression of DR after PRP (progression group), and the other 191 (78.6%) patients had stable DR (non-progression group). The progression group had higher proportion of proliferative DR (P=0.019); lower baseline visual acuity (P<0.001); and higher platelet count (P=0.048), hemoglobin (P=0.044), and hematocrit, (P=0.042) than the non-progression group. In the multivariate logistic regression analysis for progression of DR, baseline visual acuity (HR: 0.053, P<0.001) and platelet count (HR: 1.215, P=0.031) were identified as risk factors for progression. Consequently, we propose that patients with low visual acuity or high platelet count are more likely to have progressive DR despite PRP and require careful observation. Also, the evaluation of hemorheological factors including platelet counts before PRP can be considered useful in predicting the prognosis of DR.
引用
收藏
页数:10
相关论文
共 34 条
[1]  
[Anonymous], 1991, OPHTHALMOLOGY, V98, P807
[2]  
[Anonymous], 1991, OPHTHALMOLOGY, V98, P786
[3]  
[Anonymous], 1991, OPHTHALMOLOGY, V98, P741
[4]  
[Anonymous], 1976, Am J Ophthalmol, V81, P383
[5]   Incidence and Risk for Developing Proliferative Diabetic Retinopathy after Photocoagulation for Diabetic Maculopathy [J].
Bek, Toke .
CURRENT EYE RESEARCH, 2020, 45 (08) :986-991
[6]   Outcomes with As-Needed Ranibizumab after Initial Monthly Therapy Long-Term Outcomes of the Phase III RIDE and RISE Trials [J].
Boyer, David S. ;
Nguyen, Quan Dong ;
Brown, David M. ;
Basu, Karen ;
Ehrlich, Jason S. .
OPHTHALMOLOGY, 2015, 122 (12) :2504-+
[7]   Factors Associated with Worsening Proliferative Diabetic Retinopathy in Eyes Treated with Panretinal Photocoagulation or Ranibizumab [J].
Bressler, Susan B. ;
Beaulieu, Wesley T. ;
Glassman, Adam R. ;
Gross, Jeffrey G. ;
Jampol, Lee M. ;
Melia, Michele ;
Peters, Mark A. ;
Rauser, Michael E. .
OPHTHALMOLOGY, 2017, 124 (04) :431-439
[8]  
Buch Archana, 2017, J Lab Physicians, V9, P84, DOI 10.4103/0974-2727.199625
[9]  
Chelico J. D., AMIA ANN S P, V381
[10]   Comparison of systemic conditions at diagnosis between central retinal vein occlusion and branch retinal vein occlusion [J].
Cho, Bum-Joo ;
Bae, So Hyun ;
Park, Sang Min ;
Shin, Min Chul ;
Park, In Won ;
Kim, Ha Kyoung ;
Kwon, Soonil .
PLOS ONE, 2019, 14 (08)